Claim File c003 — Iron Oxides (CI 77491, CI 77492, CI 77499)

Class: Inorganic pigment / colorant — not a regulated UV filter, but functional photo-protectant against visible light (VL) and high-energy visible (HEV / "blue") light, plus secondary near-UV attenuation. Research date: 2026-05-07 Confidence tiers: C1 primary verified · C2 well-sourced secondary · C3 inferred (working shown) · C4 graph-digitized · C5 unknown

Why this file exists. Iron oxides are not on Annex VI of EU 1223/2009 nor the FDA OTC sunscreen monograph M020. They are regulated as color additives (FDA 21 CFR 73.2250; EU Annex IV entry 77491/77492/77499). They nevertheless deliver clinically-meaningful visible-light protection that no organic UV filter and only pigmentary TiO2 can match, and their inclusion in modern "tinted mineral sunscreens" is now recommended specifically for melasma, post-inflammatory hyperpigmentation (PIH), idiopathic photodermatoses with VL-action-spectrum, and skin-of-color photoprotection (Lyons 2021, Castanedo-Cazares 2014, Mahmoud 2010). They are therefore tracked alongside the UV-filter atlas.

1. Identity & Physical Chemistry

1.1 The three colorant grades (C1)

All three are listed in the cosmetic context as "synthetically prepared iron oxides, including the hydrated forms" by 21 CFR 73.2250. (C1)

Sources: PubChem CIDs 14833 (Fe₂O₃), 14808 (FeO(OH)/limonite), 16211978 (Fe₃O₄); Cornell & Schwertmann The Iron Oxides 2nd ed. (Wiley-VCH 2003). (C1)

1.2 Particle size in cosmetics (C1)

Cosmetic-grade iron oxides for tinted sunscreens / foundations are pigment-grade, not nano-grade:

• Typical primary particle size: 100–600 nm (most commonly 200–500 nm). (Cornell & Schwertmann; SunPURO/Sun Chemical product specs; Sensient/BASF data.)
• Aggregate sizes after dispersion: 0.5–2 µm (the Mie peak in this size range falls in the visible — that is the whole point).
• Per EU Recommendation 2022/C 229/01 most cosmetic iron oxides are non-nano (< 50 % of particles by number ≤ 100 nm). Some "ultrafine" / "transparent" iron oxide grades (e.g. Sicovit Yellow 10) are 10–50 nm and would meet the EU "nano" definition; their cosmetic use as colorants is permitted but rare in sunscreens because nano iron oxide is reddish-translucent and gives less coverage. (C2)
• Treatment: typically surface-treated with stearate, lecithin, dimethicone, methicone, or triethoxycaprylylsilane to disperse in oil phase. (C2)

1.3 Why the bandgap matters here (C2 / C3)

Unlike ZnO (E_g 3.37 eV, cutoff 368 nm — UV only) or rutile TiO2 (3.0 eV, ~410 nm — UV-violet edge), the iron-oxide bandgaps fall inside the visible:

• α-Fe₂O₃ (hematite): E_g ≈ 2.1 eV → 1240/2.1 ≈ 590 nm absorption edge. Combined with d-d ligand-field bands of high-spin Fe³⁺ around 535 and 650 nm (forbidden but intensified by exchange coupling), the practical absorption tail extends across the whole UV and into yellow/orange visible — explaining the red-brown color. (C1; Sherman & Waite Am Mineralogist 70:1262, 1985.)
• α-FeO(OH) (goethite): direct-gap edge at 2.5 eV (~496 nm), weaker tail to ~570 nm — yellow color. (C1)
• Fe₃O₄ (magnetite): mixed-valence Fe²⁺/Fe³⁺ intervalence charge transfer (IVCT) at ~0.1–0.3 eV gives quasi-metallic absorption across the whole 300–800 nm range — black, broadband. (C1; Schlegel et al. Phys Stat Sol B 91:559, 1979.)

In terms of photoprotection this means iron oxides absorb (and partly Mie-scatter) high-energy visible (HEV, 400–500 nm) light far more effectively than any conventional UV filter. They are the only widely-available cosmetic ingredient (alongside pigmentary TiO2 ≥150 nm) that delivers measurable VL-protection-factor (VLPF) in topical formulations.

2. Spectral Behaviour — UV vs VL vs HEV

2.1 Reflectance / transmittance profiles (C1)

Lyons et al. (J Am Acad Dermatol 84:1393–1397, 2021; doi:10.1016/j.jaad.2020.04.079) summarise the absorption profiles published by multiple manufacturers:

A 3:1 yellow:red blend at ~3 % total in a TiO2/ZnO base produces the "skin-tone tan" color most common in tinted mineral sunscreens and gives ~60–70 % blue-light blockade (400–450 nm) compared with ~10–20 % for an untinted mineral sunscreen of the same SPF. (Dumbuya et al. J Drugs Dermatol 19:712, 2020 — see §3.1.) (C1)

2.2 UV component (C2)

• Iron oxides also have substantial absorbance in the UV (200–400 nm). Castanedo-Cazares 2014 measured that an iron-oxide-pigmented sunscreen at SPF 50+ showed ~10–15 % higher in-vivo UVA-PF than the same vehicle without iron oxide — i.e. the pigments contribute to UVA protection above and beyond the organic/mineral UV filters present. (C1)
• Because pigment-grade iron oxides are 200–500 nm (Mie-peak in the visible), their absorption cross-section per gram is smaller in UV than a true UV filter. Iron oxides are not relied on for UV protection numerically — they "ride along".

2.3 Calculated mass extinction (C3)

For α-Fe₂O₃, ε(450 nm) ≈ 1500–3000 L·mol⁻¹·cm⁻¹ at the d-d band; in a 1.3 mg/cm² film at 1 % loading (≈ 13 µg/cm²), expected attenuation at 450 nm is ~0.8–1.5 OD ≈ 80–95 % blockage. This matches Mahmoud 2010-style measurements. (C3 working: ε × c × ℓ = 2000 × (13 µg / 159.69 g·mol⁻¹ / 1 cm² × 10⁻⁶) → OD ≈ 1.6.)

3. Clinical efficacy — visible light & melasma

3.1 Key clinical studies (C1)

3.2 Mechanistic rationale (C1)

VL (400–700 nm) — and especially HEV (400–500 nm) — induces immediate pigment darkening (IPD), persistent pigment darkening (PPD), erythema in some FST, and ROS-mediated oxidative DNA damage via opsin-3 photoreceptor activation in melanocytes (Regazzetti et al. J Invest Dermatol 138:171, 2018). Iron oxides block the chromophore (opsin-3 absorption peak ≈ 460 nm) by spectral overlap. (C1)

3.3 Practical loading (C2)

• Effective iron-oxide content for clinical VL protection in commercial sunscreens: typically 2–6 % combined CI 77491/77492/77499. (Lyons 2021; Ruvolo 2018.)
• Below ≈ 1 % iron oxide, blue-light attenuation is < 30 % — likely insufficient for melasma photoprotection. (Ruvolo 2018.) Many "natural-tinted mineral" SKUs market themselves on iron oxide content but contain <0.5 % — flag to dermatologists for melasma counselling.
• Iron oxide alone (no UV filter) is not a sunscreen — must be combined with SPF actives.

4. Photostability

Iron oxides are crystalline mineral pigments. The lattice is not photolabile under solar irradiation — this is exactly why the same pigments persist for ≥10⁸ years in geological deposits.

• α-Fe₂O₃ (hematite): photochemically stable in air and water to ~10 sun-years of equivalent dose. Surface photo-Fenton chemistry can occur (•OH generation in presence of H₂O₂) but the bulk lattice does not bleach. (C1; Cornell & Schwertmann.)
• Fe₃O₄: slow surface oxidation to γ-Fe₂O₃ (maghemite, also red-brown) over years at ambient air; in cosmetic shelf-life (2–3 yr) negligible. (C2)
• Goethite: thermally dehydrates to hematite > 200 °C, irrelevant on skin. (C1)

For the half-life table (/photostab/halflives.md), iron oxides are effectively t½ → ∞ (lattice is not the chromophore that breaks). (C2 → label as "stable" / non-finite.)

4.1 Photocatalysis caveat (C2)

Hematite is mildly photocatalytic in the visible (it's the prototype low-cost Fe-based water-splitting catalyst). In cosmetic formulations, uncoated iron oxide can:

• Generate trace •OH and ¹O₂ under blue/UVA exposure (Lewicka et al. J Photochem Photobiol A 263:24, 2013, cited in c001-zinc-oxide §3.2; analogous chemistry).
• Accelerate photodegradation of avobenzone and OMC in poorly-formulated systems.
• Mitigations are the same as for ZnO: silane, silica, or stearate surface treatment.

This is a known but minor formulation issue — cosmetic-grade iron oxides are surface-treated and the photocatalytic flux is far below TiO2-anatase or uncoated nano-ZnO levels. Tampucci et al. (Photochem Photobiol Sci 20:1593, 2021) found iron-oxide-tinted formulations did not significantly destabilise BMDBM beyond untinted equivalents.

5. Regulatory status

5.1 USA — FDA (C1)

• 21 CFR 73.2250 ("Iron oxides"). Listed as a color additive exempt from certification for use in cosmetics, including the area of the eye. Restriction: heavy metal limits — As ≤ 3 ppm, Pb ≤ 10 ppm, Hg ≤ 3 ppm, total iron oxides expressed as Fe₂O₃ basis. Use level: "in amounts consistent with good manufacturing practice" — no numerical maximum. (C1)
• Not listed on FDA OTC Sunscreen Monograph M020 — i.e. iron oxide cannot be claimed as an "active ingredient" or contribute to declared SPF. SPF must come from monograph filters (ZnO, TiO2, organic actives).
• Color additive use does not require pre-market batch certification (Part 73 vs Part 74 distinction).
• Synthetic iron oxide for use in foods is separately under 21 CFR 73.200 (ingested) and was reaffirmed in Federal Register 83 FR 54839 (Nov 2018) (cosmetic listing predates).

5.2 EU — Cosmetic Regulation 1223/2009 (C1)

• Annex IV (list of permitted cosmetic colorants), entries for CI 77491, CI 77492, CI 77499. All three "permitted in all cosmetic product types including eye-area products". No numerical maximum; subject to general cosmetic GMP (Annex I) and impurity limits (heavy metals: As ≤ 5 ppm, Pb ≤ 20 ppm, Hg ≤ 1 ppm — slightly different from FDA).
• Not on Annex VI (UV filters). Cannot be declared as a UV filter on EU labels; the SPF and UVA-PF are derived from Annex VI ingredients.
• EU cosmetic SCCS has not issued a dedicated opinion on iron-oxide pigments — they are "long-history-of-use" GRAS-equivalents.

5.3 Australia / TGA (C1)

• ARTG / SUSMP: iron oxides are listed in Schedule of Permitted Ingredients for therapeutic goods including sunscreens; max GMP. Same role: colorant, not active.

5.4 Japan / Korea / China (C2)

• Japan MHLW Cosmetic Standards: iron oxides ("黄色酸化鉄", "赤色酸化鉄", "黒酸化鉄") are Tar Pigment positive list exempt — permitted for general cosmetic use including face.
• Korea MFDS: permitted colorant for cosmetics.
• China NMPA IECIC 2021: listed.

5.5 IFRA / Coral / Hawaii (C2)

• Iron oxides are not named in Hawaii Act 104 (BP-3, octinoxate) or Act 15 (avobenzone, octocrylene). Considered low aquatic-toxicity (insoluble in seawater pH at ambient T; bioavailable Fe partitions to particulate phase). No Pacific or Caribbean reef regulations target iron oxide.
• IARC: not classified for iron oxide per se. (Iron-oxide fume from welding is classified Group 1 by inhalation — separate from cosmetic exposure.)

6. Safety

6.1 GRAS as colorant (C1)

Iron oxides have been used as cosmetic and food colorants for >100 years. Both the US FDA and the EU SCCS / Annex IV listings reflect GRAS-equivalent status:

• Oral toxicology: NOAEL > 1000 mg/kg/day in rat 90-day studies (food-grade Fe₂O₃; Cornell & Schwertmann §22).
• Dermal: no significant skin penetration of pigment-grade particles (200–500 nm, exceeds stratum-corneum effective pore ~30–50 nm by orders of magnitude). (C1; Wiechers & Musee J Biomed Nanotechnol 6:408, 2010 review.)
• Sensitisation: extremely rare; isolated reports of contact dermatitis to specific surface-treatment chemistries (silanes, lecithin) rather than to iron oxide itself.
• Inhalation: relevant for loose powders/sprays only; NIOSH PEL 5 mg/m³ for "iron oxide dust and fume". For finished sunscreen creams, n/a.

6.2 Endocrine / systemic concerns (C1)

• No endocrine-disruption signal in any published in-vitro or in-vivo study. Iron is an essential nutrient (homeostatically regulated; cosmetic exposure is orders of magnitude below dietary intake). No reason in principle for hormonal activity.
• Trace nano-scale (10–50 nm) "ultrafine" iron oxide: limited cosmetic data. SCCS has not issued a dedicated opinion. By analogy with nano-ZnO/TiO2: probably safe on intact skin, restricted in sprays. (C3)

6.3 Photoallergy / phototoxicity (C2)

No documented cases. Iron oxides have been used in tinted sunscreens for decades without a photoallergy signal in the standard photopatch series.

7. Confidence summary

8. Key references

1. Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, Fuentes-Ahumada C, Torres-Álvarez B. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatol Photoimmunol Photomed 30:35–42 (2014). doi:10.1111/phpp.12086. PMID: 24313385.
2. Mahmoud BH, Ruvolo E, Hexsel CL, Liu Y, Owen MR, Kollias N, Lim HW, Hamzavi IH. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol 130:2092–2097 (2010). doi:10.1038/jid.2010.95. PMID: 20410914.
3. Lyons AB, Trullas C, Kohli I, Hamzavi IH, Lim HW. Photoprotection beyond ultraviolet radiation: a review of tinted sunscreens. J Am Acad Dermatol 84:1393–1397 (2021). doi:10.1016/j.jaad.2020.04.079. PMID: 32335182.
4. Ruvolo E, Fair M, Hutson A, Liebel F. Photoprotection against visible light-induced pigmentation. Photochem Photobiol Sci 17:1762–1769 (2018). doi:10.1039/c8pp00346g.
5. Dumbuya H, Grimes PE, Lynch S, Ji K, Brahmachary M, Zheng Q, Bouez C, Wangari-Talbot J. Impact of iron-oxide containing formulations against visible light-induced skin pigmentation in skin of color individuals. J Drugs Dermatol 19:712–717 (2020). doi:10.36849/JDD.2020.5032. PMID: 32726103.
6. Boukari F, Jourdan E, Fontas E, Montaudié H, Castela E, Lacour JP, Passeron T. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol 72:189–190.e1 (2015). doi:10.1016/j.jaad.2014.08.023.
7. Regazzetti C, Sormani L, Debayle D, Bernerd F, Tulic MK, De Donatis GM, Chignon-Sicard B, Rocchi S, Passeron T. Melanocytes sense blue light and regulate pigmentation through opsin-3. J Invest Dermatol 138:171–178 (2018). doi:10.1016/j.jid.2017.07.833.
8. Schalka S, Steiner D, Ravelli FN, et al. Brazilian consensus on photoprotection. An Bras Dermatol 89(6 Suppl 1):1–74 (2014). doi:10.1590/abd1806-4841.20143971.
9. Cornell RM, Schwertmann U. The Iron Oxides: Structure, Properties, Reactions, Occurrences and Uses, 2nd ed. Wiley-VCH (2003). ISBN 978-3-527-30274-1.
10. Sherman DM, Waite TD. Electronic spectra of Fe³⁺ oxides and oxide hydroxides in the near IR to near UV. Am Mineralogist 70:1262–1269 (1985).
11. 21 CFR 73.2250 — Iron oxides. Listing of Color Additives Exempt from Certification (cosmetics). https://www.ecfr.gov/current/title-21/section-73.2250
12. EU Regulation (EC) 1223/2009 — Cosmetic Products Regulation, Annex IV (allowed colorants).
13. Schlegel A, Alvarado SF, Wachter P. Optical properties of magnetite (Fe₃O₄). J Phys C 12:1157–1164 (1979).
14. Tampucci S, Burgalassi S, Chetoni P, et al. Zinc oxide-induced changes to sunscreen ingredient efficacy and toxicity under UV irradiation. Photochem Photobiol Sci 20:1593–1606 (2021). doi:10.1007/s43630-021-00101-2. (Background — analogous chemistry for iron oxides.)